Thinking of trading ABBOTT?
- 1. The company has seen a growth over the years in its share price. In 2005 it was trading at $17.37, and in 2017 it had increased to $47.50. Its acquisition history has demonstrated that the company has a solid plan to keep this trend going for a long time. 2. The numbers also show a clear bullish trend, Abbott Labs announced 2019 Q1 revenue of $7.5 billion, a 2% increase from the $7.4 billion reported in the same quarter of the previous year. The company reported net earnings of $672 million, or $0.38 per share, on a GAAP basis, compared to $409 million, or $0.23 per share, in the same period in 2018.
Trading CFDs involves significant risk of loss
How would you like to trade ABBOTT?
- Tight spreads & reliable execution
- 70+ pre-installed indicators
- Custom indicators
- 26 time frames
- Live Sentiment data
- Chart trading
- Advanced Take Profit & Stop Loss
- Depth of Market
Trading CFDs involves significant risk of loss
- Vast selection of strategies to copy
- Efficient risk management
- Can start and stop copying at your will
- Flexible allocation of funds
- Detailed performance reports
- Full transparency & access to historical data
Copy link
Trading CFDs involves significant risk of loss
For beginners:
- Great choice of available cBots for various trading strategies and risk tolerance levels
- Simple Plug and Play functionality
For advanced traders:
- Ability to create your own cBot or custom indicator
Trading CFDs involves significant risk of loss
Trade ABBOTT with Fondex. Our CFD trading platform is engineered to provide you with optimal execution speed while allowing you to access 3 different trading methods on the same interface.
1. Some times, direct organic sales increase might not always be equal to a revenue increase. Established pharmaceutical sales for Abbott Labs fell 4.9% year over year. However, this decrease was due to a 10.3% negative impact from currency fluctuations. On an organic basis, established pharmaceutical sales increased by 5.4%. 2. Medical devices undergo clinical trials and are subject to FDA approvals, so there is always the risk of a failed trial or rejection of an application.
Risk Disclaimer Fondex provides this content/feature as no more than information. In particular, no advice is intended to be provided or to be relied on as provided nor endorsed by Fondex, nor any solicitation or incentive provided to subscribe for or sell or purchase any financial instrument or to join and/or terminate any of the trading strategies. The Investor is solely responsible for the choice of the signal provider, choice of trading strategy, the choice whether to sell or purchase any financial instrument on his/her trading account and monitoring of the trading activities. All trading or investments you make must be pursuant to your own unprompted and informed self-directed position. Please keep in mind that past performance is no guarantee of future results.
For more information, please view the 'Risk Disclosure'